Erythropoietin (Epoetin / Darbepoetin): veterinary dose and monograph

At a glance

Drug class

Veterinary drug

Also known as

EPO, Epogen, Eprex, Aranesp (darbepoetin)

Species with doses

Dogs, Cats, Rabbits and Ferrets

Routes

SC, IM

Last reviewed

1 October 2026

Indications

• Non-regenerative anaemia of chronic kidney disease (the main use) — dogs and cats
• Other erythropoietin-deficiency / chronic-disease anaemias (selected)
• Symptomatic anaemia where transfusion dependence is to be reduced

Erythropoietin (Epoetin / Darbepoetin) dose by species

Doses are per administration unless stated. mg/kg doses scale with body weight; per-animal, per-quarter and infusion-rate doses are shown as the reference writes them.

Dogs

• Anaemia of CKD (epoetin alfa): UNITS/kg (epoetin). Plumb’s p.474: 100 U/kg SC three times weekly (50–100 U/kg if a slower response is acceptable) until the low end of the target haematocrit (37–45%), then twice weekly, then weekly; maintenance 75–100 U/kg 1–2 times weekly; adjust no more often than every 3 weeks (Cowgill); start 97 U/kg (48.4–145) three times weekly (Polzin). Supplement iron; monitor blood pressure. Up to 50% develop anti-EPO antibodies (pure red-cell aplasia) after 1–3 months. Plumb’s 10e pp.464–465 (dogs/cats, extra-label): 100 units/kg SC 3 times weekly until target PCV (usually 3–4 weeks); adjust no more often than every 3 weeks; if not controlled in 8–12 weeks add 25–50 units/kg every 3–4 weeks; maintenance 50–100 units/kg once to twice weekly; evaluate for epoetin resistance above 145 units/kg 3 times weekly. Darbepoetin: see next row.
• Anaemia of CKD (DARBEPOETIN alfa — µg/kg): Plumb’s 10e p.343 (extra-label): 0.5–0.8 µg/kg (MICROGRAMS, not units) SC weekly — the higher dose appears more effective; once target PCV is reached extend to the longest interval that holds it (e.g. every 14 or 21 days); intervals beyond 21 days are unlikely to work long-term. Supplement iron.

Cats

• Anaemia of CKD (epoetin alfa): UNITS/kg (epoetin). Plumb’s p.474: consider when PCV <20%; 75–100 U/kg SC three times weekly until PCV reaches the low target range (30–40%), then 50–75 U/kg twice weekly (Scherk; Chew). Give iron from the start (ferrous sulfate 5–50 mg per cat per day). Monitor PCV and blood pressure; antibody-mediated red-cell aplasia possible.
• Anaemia of CKD (DARBEPOETIN alfa — µg/kg): Plumb’s 10e p.343 (extra-label): 1 µg/kg (MICROGRAMS, not units) SC once weekly; other recommendations range 0.25–1.5 µg/kg per week. Once target PCV is met extend the interval (e.g. every 14 or 21 days). Supplement iron.

Rabbits

• Anaemia: UNITS/kg. Plumb’s p.474 (Ivey & Morrisey 2000): 50–150 U/kg SC every 2–3 days until PCV is normal, then weekly for at least 4 weeks.

Ferrets

• Anaemia: UNITS/kg. Plumb’s p.474 (Williams 2000): 50–150 U/kg IM three times weekly, reducing to weekly once RBC indices improve.

Contraindications

Uncontrolled hypertension (EPO raises blood pressure). Iron deficiency without supplementation (EPO won't work). Known hypersensitivity. Over-rapid correction / targeting a normal-high haematocrit (thrombosis/hypertension risk). Prior anti-EPO antibody reaction. Pregnancy (caution).

Species-specific warnings

Cats: CKD cats are the classic patients — use darbepoetin (less PRCA risk), supplement iron, monitor blood pressure and haematocrit, and target a modest HCT.

Adverse effects

• ANTI-EPO ANTIBODY formation → refractory pure red cell aplasia (worse with epoetin than darbepoetin)
• Systemic HYPERTENSION (monitor/treat)
• Iron depletion (functional) — needs iron supplementation
• Injection-site reaction; polycythaemia/thrombosis if over-corrected; seizures (rare, rapid rise)

Drug interactions

• Iron status: adequate iron is REQUIRED for a response (functional iron deficiency develops) — co-supplement iron
• Antihypertensives: may be needed to control EPO-induced hypertension
• No major small-molecule pharmacokinetic interactions

Pregnancy and lactation

Limited data; use only if clearly needed.

Monitoring

• Haematocrit/PCV (titrate to a TARGET ~30–35 %, not normal-high) and reticulocytes
• Iron status (supplement iron) — required for response
• Blood pressure (EPO-induced hypertension)
• Watch for a plateau/decline in HCT despite therapy = possible anti-EPO antibody PRCA (stop the drug)

Toxicity and overdose

The defining veterinary hazard is immune-mediated: anti-EPO antibodies can neutralise the drug and cross-react with endogenous EPO, causing a worsening, transfusion-dependent PURE RED CELL APLASIA (more common with epoetin; darbepoetin is less immunogenic). Other effects: hypertension, polycythaemia/thrombosis and seizures if the haematocrit is raised too high/too fast, and functional iron deficiency. Hence targeting a modest (not normal) haematocrit and monitoring.

Management: No specific antidote. For over-correction (polycythaemia/hypertension), withhold the drug and manage blood pressure; phlebotomy if severe polycythaemia. If PRCA develops, STOP the drug (it perpetuates the problem) and support with transfusions ± immunosuppression; recovery of endogenous EPO may occur over time. Monitor HCT/blood pressure.

Clinical pearls

• The treatment for the anaemia of chronic kidney disease — it does what the failing kidney can't (make EPO); prefer DARBEPOETIN (less immunogenic, weekly dosing) over epoetin
• ALWAYS co-supplement IRON (EPO fails without it) and monitor BLOOD PRESSURE (it causes hypertension)
• Target a MODEST haematocrit (~30–35 %), not a normal one — over-correction risks hypertension, thrombosis and seizures
• The dreaded complication is antibody-mediated pure red cell aplasia (HCT falls despite treatment, transfusion-dependent) — recognise it and STOP the drug; darbepoetin lowers this risk

Mechanism of action

Recombinant erythropoietin (and the hyperglycosylated, longer-acting darbepoetin) binds erythropoietin receptors on erythroid progenitor cells in the bone marrow, stimulating their proliferation, differentiation and survival into mature red blood cells — replacing the erythropoietin that a diseased kidney fails to produce and thereby correcting the anaemia. Because they are human/engineered proteins, they can provoke neutralising antibodies in animals; darbepoetin's modified structure is less immunogenic and longer-acting (less frequent dosing).

Formulations and products

• Epoetin alfa 2000 / 4000 / 10000 IU vial/syringe
• Darbepoetin alfa 25 / 40 / 60 mcg syringe (long-acting)
• Eprex / Epogen (epoetin) — 2000 / 4000 / 10000 IU, SC/IV injection (human-label)
• Aranesp (darbepoetin) — 25 / 40 / 60 mcg syringe, SC injection (long-acting) (human-label)

Storage

Refrigerate (2–8 °C), do NOT freeze; protect from light. Do not shake (protein). Discard if frozen/discoloured.

Before you use this dose

Reference doses for veterinary professionals. Confirm the dose against the product label, the patient’s condition, current guidance and local regulations before use; the attending veterinarian remains responsible for every clinical decision.

Other hormones, emergency drugs, supplements and other drugs

• Doxapram
• Doxorubicin
• Enoxaparin
• Epinephrine
• Estriol
• Ferrous Sulfate
• Finasteride
• Fludrocortisone

Frequently asked questions